

Genetic prevalence of antifungal resistance gene in cancer patients with Oropharyngeal Candidiasis from Iraq

Muhammed Abd ulrahman Majeed  , Abdulameer Jasim Mohammed*  , Omar Sadik Shalal  

Medical Laboratory Techniques Department, College of Health and Medical Techniques, Middle Technical University, Baghdad, Iraq.

*Corresponding author.

Received 12/09/2023, Revised 04/11/2023, Accepted 06/11/2023, Published Online First 20/05/2024, Published 01/12/2024



© 2022 The Author(s). Published by College of Science for Women, University of Baghdad.

This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

As the population of immunocompromised patients grew, yeast infections became more common. There has been a significant rate of morbidity and mortality among patients with Candidiasis demonstrating increased resistance to antifungal medications. The main aim of this study was to determine the virulence gene of *Candida albicans*, evaluate antifungals used for Candidiasis, and biofilm formation, which is isolated from the mouth of individuals in the Baghdad Governorate From 1st October 2022 to 28th February 2023. This study included 120 oral swabs collected from people who had oral candidiasis, with an age group between 10-65 including both Genders. The results obtained showed that the candidiasis frequency was more prevalent in males between the age group of 11-20 years. These results showed a statistically significant increase in the prevalence of ERG11 virulence gene among the biofilm-forming *C. albicans* fungus compared to other isolates with a significant difference ($P = 0.863$). Also, the study showed significant resistance of *C. albicans* to the antifungals fluconazole, itraconazole and fluconazole with the ability to form a biofilm. The present study also highlighted an elevated prevalence of the ERG11 gene in *C. albicans* and a strong association between the formation of biofilms and the presence of virulence gene was noted. Candidiasis is one of the fungal infections that are more prevalent among patients, and the virulence factor biofilm has an important role in increasing the pathogenicity of the fungus.

Keywords: Antibiotic susceptibility, Biofilm, *Candida albicans*, ERG11, virulence.

Introduction

The most common fungus pathogen of humans and a common commensal of the mammalian microbiome are both called *Candida albicans*. They are found primarily on human mucosal surfaces such as the gastrointestinal and urogenital tracts as a commensal and most commonly cause invasive disease as a result of alterations in the normal microbiological flora, breaches in the mucocutaneous barrier, or defects in the host cellular response. In addition to the

traditional risk factors for developing IFDs, the presence of central venous catheters, the use of total and parenteral nutrition, the use of indwelling urinary catheters, and the use of broad-spectrum antibiotics increase one's risk of developing invasive candidiasis¹. Species of the genus *Candida* are part of the common microbiota of humans; however, some of the *Candida* species are known opportunistic pathogens.

Formation of biofilms, resistance to antifungal drugs, and increase in asymptomatic infections demand more studies on the isolation, identification and characterization of *Candida* from clinical samples^{2,3}. *Candida* infections, whether caused by *C. albicans* or another species, have increased dramatically⁴. Members of the *Candida* genus, most often *C. albicans* and non-*albicans* spp., caused the majority of yeast infections. Patients with weakened immune systems, such as those suffering from diabetes, AIDS, malignant tumors, or solid organ transplants, are more vulnerable to candidiasis⁵. The "virulence factors" present in yeast cells, such as biofilm, pigments, and extracellular hydrolytic enzymes, boost cell virulence⁶.

Candidiasis is frequently accompanied by the formation of a biofilm (BF), which can occur both in vivo, such as the oropharyngeal surface, and in vitro, such as catheter and indwelling device surfaces.⁷ These biofilms are made up of tightly packed micro colonies of cells that form a complex structure that increases drug resistance to drugs such as nystatin, Azole, and amphotericin B^{7,8}. These factors increase the pathogen's ability to survive, invade, and disseminate to other organs⁵. *Candida* infection can vary depending on the site of infection; oral candidiasis is the most frequent kind⁹. Immunocompromised people have more *Candida* species colonization than healthy people⁹. Cancer patients with oral candidiasis have colonization levels ranging from 30% to 50%¹⁰. *C. albicans* has been recognized as the primary source of fungal illnesses in cancer patients¹¹.

Numerous investigations on the formation of biofilms and extracellular hydrolytic enzymes (proteinase, phospholipase, and lipase) have been undertaken¹¹. They were discovered to have a strong relationship with yeast pathogenicity by enhancing adhesion, penetration, host defense modulation, or colonization¹². Yeast cells, on the other hand, aggregate form a thin covering known as a biofilm that adheres to solid surfaces¹³. This layer, however, has a thin, strong appearance and characteristics associated with pathogenicity and antifungal medication resistance¹⁴. Azoles are the first-line antifungals utilized in therapy. By encoding the gene ERG11 (Erg11p), the azoles work by inhibiting

lanosterol 14-demethylase, an enzyme that aims to limit the biosynthesis of ergosterol, which is required for the synthesis of the cell membrane of fungi resistant to azoles. Lanosterol 14-demethylated azoles are produced by mutagenesis and gene expression of the ERG11 gene¹⁵.

Candida frequently sticks to biomedical equipment and develops into a hardy biofilm that may survive extremely high antifungal doses. The central venous catheter (CVC), which is used to infuse fluids, nutrition, and/or cytotoxic medications, is the medical device that is most frequently contaminated by *Candida* biofilms. The distal tip of the catheter can be contaminated at the time of insertion or, alternatively, organisms can migrate down the catheter wound, but more frequently, *Candida* can have its origin on the patient's skin or the hands of nursing staff¹⁶.

The ability of each species to create extracellular polymeric substances (EPS) and exhibit dimorphic growth, as well as the substratum of the biofilm, the accessibility of carbon sources, and other factors, all affect the biofilm's features. Additionally, pathogenic yeasts of the *Candida* genus exhibit a high degree of complexity and diversity in the transcriptional regulation of activities like adhesion, biofilm formation, filamentation, and EPS generation. The antifungal resistance that is typically present in *Candida* biofilm cells, potentiated by EPS, which acts as a barrier to drug diffusion, and by the overexpression of drug resistance transporters, has implications for both the persistence of colonization and infections¹⁷.

In the plasma membrane of *Candida* cells, ergosterol predominates over all other sterols. Additionally, antifungal medications (such as azoles and amphotericin B) function as ergosterol synthesis inhibitors by attaching to the particular enzyme lanosterol demethylase involved in the manufacture of this sterol. The discovery that *Candida* mutants with altered ergosterol production exhibit increased resistance to azoles and amphotericin B prompted the researchers to wonder whether *Candida* biofilm cells might use comparable mechanisms of resistance¹⁸.

Numerous investigations revealed that when comparing the membranes of biofilm cells to those

of planktonic cells, the latter exhibited a lower content of ergosterol, particularly during the latter stages of biofilm development. This study shows that ergosterol is not as important for maintaining membrane fluidity in cells from established biofilms, which may restrict the effectiveness of medications that target ergosterol. In fact, numerous investigations have shown that different *Candida* species have altered sterol pathway genes' transcriptional profiles. When compared to their planktonic counterparts, ERG25 and ERG11 in vitro biofilm development increased according to a *C. albicans* microarray investigation¹⁷.

Materials and Methods

Patients and Samples collection: Between October 1st, 2022 and 28th February 2023, 120 male and female patients with cancer were admitted to Medical City, Specialist Children's Hospital, Baghdad Hospital, and Central Teaching Hospital of Pediatrics. To complete this project, Middle Technical University/College of Health and Medical Techniques/Department of Medical Laboratory Techniques inked agreements. A sterile pre-moistened swab was used to collect duplicate samples of oral thrush. The clinical mycology laboratory received all samples. The process of collecting samples was done by rinsing the mouth with 10 ml of sterile water for half a minute, and the rinse components were settled by centrifugation for 15 minutes at 2000 rpm. In ideal conditions, 37 °C, *C. albicans* were dispersed by germ tube formation experiment (2 hours in serum at 37 °C), after which microscopic examination was carried out to reveal the germ tube¹⁹. Chlamydospore production on Corn Meal Agar (CMA), colony color on CHROMagar *Candida* medium a (CHROMagar, Paris, France),

Conventional Identification

Plate-Base Method: After preparing the samples, the type of *Candida* was diagnosed using a chromogenic candida luminescent agar (BCA) medium, according to the manufacturer's instructions,¹² Sub-cultured isolates were then incubated for 2 days at 37°C. The yeast colony color on the plate was used for identification and growth was evaluated every day for 3 days.

In Iraq, there is not much research or scarcity of research and information regarding the drug resistance of fungi and its molecular mechanisms, especially in *C. albicans*. Therefore, this research was designed to find out the prevalence of disease causing *C. albicans* and its resistance to antifungals. We also aimed to find the prevalence of ERG11 responsible for antibiotic resistance among the isolates isolated from the mouth and pharynx of subjects¹⁶.

Germ Tube Test: *C. albicans* germ tube assay was performed for all yeast isolates and other related isolates by adding each isolate to 0.5 ml of human blood serum in a test tube. After incubation for 3 hours at 37 °C, 1–2 drops of the suspension were added to 10% KOH onto the slide and examined under a light microscope to examine the germ tubules.^{13,15}

Detection of Virulence Factor

Biofilm formation: The biofilm formation of the isolated yeasts was investigated were evaluated by the method described by Coffey BM et al²⁰. Fungal cultures grown overnight in Sabouraud dextrose broth were diluted in sterile saline to 0.5McFarland (1.5×10^8 CFU/mL). About 15µl of this fungal suspension was added to 96-well microplates containing 150µl of Sabouraud broth. The plates were then incubated at 37°C for 24- 48 hr to facilitate biofilm growth. Following incubation, the wells were washed with PBS and stained with crystal violet (0.1%) for 15min. The stained cells were then decolourized with 33% acetic acid and the absorbance was recorded at 492nm was measured in Genetix microplate reader. The biomass adhered to is estimated to be proportional to the absorbance. The intensity of the biofilm growth was assessed using OD cut-off values¹⁵.

Antifungal susceptibility testing: The antifungal sensitivity test was done using the Kirby-Bauer disk diffusion method¹². In brief, the inoculum was adjusted to 0.5McFarland with saline. Standard

antifungals (Liofilchem R srl, Italy) like Fluconazole FLU (100mg), Itraconazole ITR (50mg), Nystatin NY and Amphotericin B were added to their respective wells and incubated at 37°C for 24-48hr. Following incubation, inhibition zones were measured in millimeters and the findings were interpreted using interpretative breakpoints established by CLSI/EUCAST for in vitro sensitivity testing²¹.

DNA extraction and PCR amplification: The extraction of DNA was done, based on bead beating tube and spin columns as described by gene aid²². Primer for ERG11 gene (F: 5'-GCAGCA GCA GTA TCCCATCT-3', R: CTCATGGGGTTGCCAATGTT-3'²³. Was

designed using primer 3 software and procured from Sigma Aldrich. ERG11 gene was found to be responsible for the resistance against azole exposure in *C. albicans*. Amplitaq Gold master mix was used in the amplification using the System PCR 9700 of GeneAmp Thermocycler (Applied Biosystems, CA, USA). DNA polymerase (5U/L), 125mM MgCl₂; and 10 mM dNTP mixture. The PCR was performed in a total reaction volume of 10.5µl. 2µl of each primer was added to the master mixture. Then the following amplification protocol: 95°C for 5min for Initial denaturation, then 35 cycles of denaturation at 95°C for 1min, Annealing at 53°C for 30sec, and the elongation step was at 72°C for 2min. The amplicons were separated on 1.5% agarose gel using TBE buffer. PCR product to be expected at 751bp.

Table 1. Table showing the primer sequence used for the molecular study of the isolated *C. albicans*.

Gene	Sequence of Primers	Annealing Temp.	Size of Amplicon (bp.)
CALBI	FW GCAGCACAGCAGTATCCCATC RV CTCATGGGGTTGCCAATGTT	59.8	751bp

Statistical analysis: The statistical analyses were performed using SPSS (Statistical Package, Version 20.0). The variables were subjected to student's t-test

and were tested for significance at p<0.05. The SD, which was calculated using Microsoft Excel 2010, was used to quantify the dispersion.

Results and Discussion

Study population: The present study comprised 120 male and female patients diagnosed with cancer and were hospitalized at Medical City Specialist Children's Hospital, Baghdad Hospital, and Central Teaching Hospital of Pediatrics. The observed results were about 45.83% (55/120) of the subjects was females and the rest 54.16% (65/120) were male. A significant observation was funded, where a larger proportion of females (27.27%) to be in the age group of less than 10 years old (15/55). And a higher percentage of males (30.77%) are in the age group of 11-20 years old (20/65). Further, also had confirmed data, where the majority of patients had inflammatory symptoms of oral candidiasis, like severe pseudomembranous candidiasis, oropharyngeal candidiasis, and angular cheilitis.

After incubation, 90% (100 of the samples) of the positive sample swabs showed development on

the SDA plates, whereas the rest samples did not. The morphological identification of the entire positive (n=90) samples was investigated, for the development of colonies on Brilliant green and the formation of germ tubes. Among the cultured isolates about 92 and 83% showed positive growth on SDA and CHROM agar respectively. On the other hand, about 83% showed the development of germ tubes (Table 2, Fig. 1)

Table 2. *C. albicans* growth on Saubrouds Dextrose Agar (SDA), Germ tube and CHROM agar culture)

	SDA	Germ tube	CHROM agar
Number positive	110	100	100
Percentage	92%	83%	83%




Figure 1. Photographic images showing A: germ tube formation in *candida albicans*; B: *candida albicans* on Brilliance candida agar (BCA).

Table 3. Table showing the antibiotic susceptibility in *C. albicans* isolated from the patients. (n=90). All the values are average of triplicates.

Antifungal	Sensitive (%)	Resistance (%)	Intermediate (%)	Total no.
Flucanazole	16.60	72.20	11.11	90
Itrconazole	33.30	61.11	5.55	
Nystatin	88.88	1.12	10	
Amphotericin B	94.44	0	5.56	

According to the Clinical and Laboratory Standards Institute criteria, the antifungal susceptibility test revealed that resistance impacted all of the families evaluated in this investigation. The isolated strains showed less susceptibility to Flucanazole (72.20%) followed by Itraconazole (61.11%). Among the 90 isolates tested, almost all of them were found to be susceptible to Amphotericin B. There were no resistant isolates observed for Amphotericin B. Among the sensitive isolates 94.44% were found to be highly sensitive and 5.56% were intermediate. (Table 3)

Antifungal

susceptibility testing: With the ability of *C. albicans* to form a biofilm, its resistance to antifungal drugs increased, and the increase was as follows for the biofilm-forming isolates: flunazole, itraconazole, amphotericin B, and nystatin (83.1%, 67.5%, 5.2%, and 11.7%, respectively) compared to isolates that did not form biofilm (84.6%, 61.5%, 7.7% and 7.7%, respectively). There was a significant increase in the prevalence of ERG11 virulence gene (96.6%) among biofilm-forming isolates compared to non-biofilm-forming isolates (11.9%).

Table 4. Comparison between biofilm forming *C. albicans* and non-biofilm forming *C. albicans*.

n = 90	Biofilm forming	Non-biofilm forming	P value
	85.6%	14.4%	
Nystatin	11.70%	7.70%	P=0.672
Fluconazole resistance	83.1%	84.60%	P=0.893
Itraconazole resistance	67.50%	61.50%	P=0.672
Amphotericin B resistance	5.20%	7.70%	P=0716

The result after chi square performed was non-significant >0.05 so there we deduced no significant relation between biofilm formation and antifungal resistance.

Antifungal susceptibility tests in *C. albicans*

The *invitro* An antifungal susceptibility study was conducted on five antifungals used for *C. albicans*

showed that all *C. albicans* isolates (100%) were susceptible to AMB, ITC, VRC and CAS with MICs range from ≤ 17 mm The result was resistance into fluconazole and itraconozole (Fig. 2) and this resistance help to survive and increase pathogenicity. According to the Clinical and Laboratory Standards Institute criteria, the antifungal susceptibility test

revealed that resistance impacted all of the families evaluated in this investigation.



Figure 2. Plate showing the inhibition zones with different antifungals against *C. albicans*.

Evaluation of Virulence Factor: In the table was presented, the results of the biomass of the biofilms (Bm) of the candida. In the current study, the results showed the ability of *C. albicans* to produce biomass. After 72hr of incubation high, low and moderate biofilm producers were found to be 81.11, 5.56 and 13.33 respectively.




Figure 3. Graph showing the percent of biofilm producers. All the values are average of triplicates. High, low and intermediate percentage can be seen in the graph.

Virulence Factor Evaluation.

This study looked at the virulence factor, as well as the isolate's capacity to biofilm. Biofilm formation may contribute aggressively to both systemic and superficial candidiasis by increasing

antifungal resistance. In the current study, the potential for producing thin biofilms was classified into three categories: high, medium, and poor, and then the results were evaluated by measuring the number of adhering cells from *C. albicans* at the bottom of the well using cut-off values OD and under microscopic magnification 40 and for three different times after three days (72) hours. The outcome was 65% strong, 21% low, and 14% intermediate (Table 3).

Antifungal resistance: The result was resistance to fluconazole and itraconazole (Fig. 3) and these resistances help to survive and increase pathogenicity. Detection of antifungal susceptibility test results, all fungal strains that were evaluated according to the criteria of the Clinical and Laboratory Standards Institute were investigated in this study.

Table 5. Table showing the percent of biofilm producers and antifungal resistance developed within the strain after 72hr incubation.

Results After 72hr	Biofilm	Antifungal
Strong	65%	60% resistance
Intermediate	21%	12% resistance
Low	14%	1% resistance

The relation between biofilm and antifungal:

Stronger the biofilm formation, more is the resistance to antifungals is seen after 72hr of incubation. Stronger (65%) biofilms were found to be 60% resistance, while intermediate (21%) were found to be 12% resistance.

Determination of mutated *ERG11* gene: Only *C. albicans* strains with one of azole resistance genes were chosen for the identification of the resistance gene (*ERG11*). In total. The DNAs of 30 isolates (*C. albicans*) were tested. 8 of the isolates exhibited the *ERG11* resistance gene. (Fig. 4) shows the depiction of bands acquired via UV visualization following agarose gel electrophoresis.



Figure 4. Gel electrophoresis of simplex PCR products of ERG11 gene of *C.albicans* on 1% agarose gel at 75 Volt /cm for 1 hour. Lane 1: 1000bp DNA ladder.

Discussion

Candida is a fungus that belongs to the normal flora of the oral cavity which is pathogenic under certain conditions. It can be a cause of opportunistic infections when the host immune system is impaired⁸. *C. albicans* is known to be carried out in the oral cavity of 50 % of the world's population as a part of normal flora. There is a higher prevalence of *Candida* carriage in the oral cavity of immunocompromised patients when compared with a healthy population²⁴. Invasive infections in the mucosa lining the oral cavity of immunocompromised patients is the results of the colonization of *C. albicans*. The prevalence of *C. albicans* in the oral mucosa of cancer patients in general (100%) and in our current study the antifungal susceptibility profile showed that all

tested isolates were sensitive to FLC, NYS, AMB, VRC.

The results of the study of the activity of the thin biofilms of *C. albicans*, measured using violet crystal, were the highest activity of *C. albicans* with high levels, followed by medium and then low²⁵.

In our study, antifungal resistance as a virulence factor is an important step in fungal pathogenicity. *C. albicans* had the highest frequency of ERG11 genes. This result was similar to previous studies in Iraq and Iran²⁶. That showed that expression of ERG11 in *C. albicans* plays an important role in the spread of *Candida* infection.

Conclusion

The awareness of oral candidiasis, and the reduction of risk factors associated with oral candidiasis such as the use of dental prosthesis in patients with CA are essential. Furthermore, it is necessary to identify *C. albicans*, in understanding and defining the pathogenesis and antifungal susceptibility of candidiasis. The present study highlights the prevalence of resistance to antifungal drugs among *C. albicans* which are not uncommon.

Moreover, there was a high prevalence of ERG11 gene in *C. albicans*. The resistance to antifungal drugs was common among isolates with the capacity to form the biofilm. There was an association between biofilm formation and virulence genes. Candidiasis is one of the fungal infections that are more prevalent among patients, and the virulence factor biofilm has an important role in increasing the pathogenicity of the fungus.

Acknowledgment

We would express our thanks to the University Middle technical university/college of health and

medical techniques/ department of Medical Laboratory Techniques and supporting this work. The project was funded by authors.

Authors' Declaration

- Conflicts of Interest: None.
- We hereby confirm that all the Figures and Tables in the manuscript are ours. Furthermore, any Figures and images, that are not ours, have been included with the necessary permission for re-publication, which is attached to the manuscript.
- Authors sign on ethical consideration's approval.
- No animal studies are present in the manuscript.
- Ethical Clearance: The project was approved by the local ethical committee at University of Baghdad.

Authors' Contribution Statement

This work was carried out in collaboration between all authors "Conceptualization, methodology, software, validation, formal analysis, investigation,

resources, data curation, writing and writing original draft preparation .review and editing, visualization, supervision and project administration.

References

1. Tortorano AM, Prigitano A, Morroni G, Brescini L, Barchiesi F. Candidemia: evolution of drug resistance and novel therapeutic approaches. *Infection and Drug Resistance*. 2021 Dec 19:5543-53. <https://doi.org/10.2147/IDR.S274872>
2. Satish T Pote, Mahesh S Sonawane, Praveen Rahi, Sunil R Shah, Yogesh S Shouche, Milind S Patole, et al. Distribution of Pathogenic Yeasts in Different Clinical Samples: Their Identification, Antifungal Susceptibility Pattern, and Cell Invasion Assays. *Infect Drug Resist*. 2020; 13: 1133–45. <https://doi.org/10.2147/IDR.S238002>
3. Chakraborty M, Banu H, Gupta MK. Epidemiology and Antifungal Susceptibility of Candida Species causing Blood Stream Infections: An Eastern India Perspective. *J Assoc Physicians India* . 2021 Aug; 69(8): 11–12.
4. Boan P, Gardam D. Epidemiology and antifungal susceptibility patterns of candidemia from a tertiary centre in Western Australia. *J Chemother* . 2019; 31(3): 137–40. <https://doi.org/10.1080/1120009X.2019.1595895>
5. Rodrigues CF, Rodrigues ME, Henriques M. Candida sp. Infections in Patients with Diabetes Mellitus. *J Clin Med* . 2019; 8(1). <https://doi.org/10.3390/jcm8010076>
6. Rodrigues AG. Yeast Engineering for New Antifungal Compounds: A Contextualized Overview. In: Hesham AE-L, Upadhyay RS, Sharma GD, Manoharachary C, Gupta VK, editors. *Fungal Biotechnology and Bioengineering* . Cham: Springer International Publishing; 2020. p. 17–36. https://doi.org/10.1007/978-3-030-41870-0_2
7. Sarsaiya S, Shi J, Chen J. Current Progress on Endophytic Microbial Dynamics on Dendrobium Plants BT - Fungal Biotechnology and Bioengineering. In: Hesham AE-L, Upadhyay RS, Sharma GD, Manoharachary C, Gupta VK, editors. Cham: Springer International Publishing; 2020. p. 397–418. https://doi.org/10.1007/978-3-030-41870-0_17
8. Damphousse CC, Miller N, Marrone DF. Experience-Dependent Egr1 Expression in the Hippocampus of Japanese Quail. *Front Psychol* . 2022; 13. <https://doi.org/10.3389/fpsyg.2022.887790>
9. Santos ALS dos. Aspartic Peptidase Inhibitors as Potential Bioactive Pharmacological Compounds Against Human Fungal Pathogens. In: Ahmad I, Owais M, Shahid M, Aqil F, editors. *Combating Fungal Infections: Problems and Remedy* . Berlin, Heidelberg: Springer Berlin Heidelberg; 2010. p. 289–325. https://doi.org/10.1007/978-3-642-12173-9_13
10. Lakshmy J, Katragadda R, Balaji J. Speciation and antifungal susceptibility of esophageal candidiasis in cancer patients in a tertiary care hospital in South India. *J Med Allied Sci*. 2016; 6: 29.
11. Abeed FK, Alrubayae IMN. Evaluation of virulence factors of clinical yeast isolates from nosocomial fungal infections with the determination of their antifungal susceptibility profile. *Iran J Ichthyol*. 2022; 9(Special Issue 1 (ABC)): 61–8.
12. Farmakiotis D, Kontoyiannis DP. Epidemiology of antifungal resistance in human pathogenic yeasts: current viewpoint and practical recommendations for management. *Int J Antimicrob Agents* . 2017; 50(3): 318–24.

- <https://doi.org/10.1016/j.ijantimicag.2017.05.019>
13. Amarasinghe AAPBN, Muhandiram MRS, Kodithuwakku SP, Thilakumara IP, Jayatilake JAMS. Identification, genotyping and invasive enzyme production of oral *Candida* species from denture induced stomatitis patients and healthy carriers. *J Oral Maxillofac Surgery, Med Pathol* . 2021; 33(4): 467–74. <https://doi.org/10.1016/j.ajoms.2021.02.004>
 14. Fonseca VJA, Braga AL, de Almeida RS, da Silva TG, da Silva JCP, de Lima LF, et al. Lectins ConA and ConM extracted from *Canavalia ensiformis* (L.) DC and *Canavalia rosea* (Sw.) DC inhibit planktonic *Candida albicans* and *Candida tropicalis*. *Arch Microbiol* . 2022; 204(6): 346. <https://doi.org/10.1007/s00203-022-02959-x>
 15. Zottich U, de Oliveira IS, Fereira IG, Cerni FA, Karla de Castro Figueiredo B, Arantes EC, et al. Antifungal activity of *Rhopalurus crassicauda* venom against *Candida* spp. *Toxicon X* . 2022; 14: 100120. <https://doi.org/10.1016/j.toxcx.2022.100120>
 16. Perlin DS. Antifungals: From Genomics to Resistance and the Development of Novel Agents. *Clin Infect Dis*. 2015 Oct 1; 61(7): 1213–4. <https://doi.org/10.1093/cid/civ548>
 17. Yapar N. Epidemiology and risk factors for invasive candidiasis. *Ther Clin Risk Manag*. 2014; 10: 95–105. 18. Lattif AA K, Mukherjee P, Chandra J, Swindell K, Lockhart SR, Diekema DJ, et al. Characterization of biofilms formed by *Candida parapsilosis*, *C. metapsilosis*, and *C. orthopsilosis*. *Int J Med Microbiol* . 2010; 300(4): 265–70. <https://doi.org/10.1016/j.ijmm.2009.09.001>
 19. Fiallos N de M, Ribeiro Aguiar AL, da Silva BN, Pergentino MLM, Rocha MFG, Sidrim JJC, et al. The Potential of Phenothiazines against Endodontic Pathogens: A Focus on *Enterococcus-Candida* Dual-Species Biofilm. *Antibiotics*. 2022; 11(11). <https://doi.org/10.3390/antibiotics11111562>
 20. El-Ashmony MM, Raslan FS, Abdelhamid DH, Hafez HM, Abd El-Rahman OA. Potential Antifungal Activity of Lactobacilli Probiotic Against Fluconazole Resistant *Candida albicans* Clinical Isolates. *Azhar Int J Pharm Med Sci* . 2023; 3(1): 120–31. <https://doi.org/10.21608/aijpm.2022.131769.1123>
 21. Abu-Mejdad N. Isolation and molecular identification of yeasts, study their potential for producing killer toxins and evaluation of toxins activity against some bacteria and pathogenic fungi. 2020 Feb. <http://dx.doi.org/10.13140/RG.2.2.35900.59528>
 22. Dovo EE, Zohoncon TM, Tovo SF, Soubeiga ST, Kiendrebeogo IT, Yonli AT, et al. First detection of mutated ERG11 gene in vulvovaginal *Candida albicans* isolates at Ouagadougou/Burkina Faso. *BMC Infect Dis*. 2022; 22(1): 678. <https://doi.org/10.1186/s12879-022-07619-5>
 23. Nouraei H, Jahromi MG, Jahromi LR, Zomorodian K, Pakshir K. Potential Pathogenicity of *Candida* Species Isolated from Oral Cavity of Patients with Diabetes Mellitus. Garg H, editor. *Biomed Res Int* . 2021; 2021: 9982744. <https://doi.org/10.1155/2021/9982744>
 24. Castelo-Branco D de SCM, Paiva M de AN, Teixeira CEC, Caetano ÉP, Guedes GM de M, Cordeiro R de A, et al. Azole resistance in *Candida* from animals calls for the One Health approach to tackle the emergence of antimicrobial resistance. *Med Mycol* . 2020 Oct 1; 58(7): 896–905. <https://doi.org/10.1093/mmy/myz135>
 25. Mohammadi F, Hemmat N, Bajalan Z, Javadi A. Analysis of Biofilm-Related Genes and Antifungal Susceptibility Pattern of Vaginal *Candida albicans* and Non-*Candida albicans* Species. Cantore S, editor. *Biomed Res Int*. 2021; 2021: 5598907. <https://doi.org/10.1155/2021/5598907>
 26. Henry, K. W., Nickels, J. T., & Edlind, T. D. Upregulation of ERG genes in *Candida* species by azoles and other sterol biosynthesis inhibitors. *Antimicrob Agents Chemother*. 2000; 44(10),2693–2700. <https://doi.org/10.1128/AAC.44.10.2693-2700.2000>

السمة الوراثية لجين مقاومه المضادات الفطرية لدى المرضى العراقيين

محمد عبد الرحمن مجيد ، عبد الامير جاسم، عمر صادق شلال

تقنيات المختبرات الطبية، التقنيات الصحية والطبية، التقنيه الوسطى، بغداد، العراق.

الخلاصة

مع تقدم الطب وتزايد عدد المرضى الذين يعانون من ضعف المناعة، أصبحت عدوى الخميرة أكثر شيوعاً. كان هناك معدل كبير من الأمراض والوفيات بين المرضى الذين يعانون من داء المبيضات مما يدل على زيادة المقاومة للأدوية المضادة للفطريات. الهدف الرئيسي من هذه الدراسة هو تحديد جين الضراوة لفطر المبيضات البيضاء وتقييم مضادات الفطريات المستخدمة لداء المبيضات وقابلية تكوين الأغشية الحيوية التي يتم عزلها من أنسجة المبطّن للفم عند الأفراد في محافظة بغداد خلال الفترة من 1 تشرين الأول إلى 28 شباط 2023. وتضمنت هذه الدراسة 120 مسحة فموية من أشخاص مصابين بداء المبيضات الفموي، تتراوح أعمارهم بين 10-65 سنة من كلا الجنسين. أظهرت النتائج التي تم الحصول عليها أن انتشار داء المبيضات كان أكثر انتشاراً في الذكور الذين تتراوح أعمارهم بين 11-20 سنة، بينما كان أكثر انتشاراً بين الإناث بين المرضى أقل من 10 سنوات. أظهرت هذه النتائج زيادة ذات دلالة إحصائية في انتشار جين الفوعة ERG11 بين فطر المبيضات البيض المكون للأغشية الحيوية مقارنة بالعزلات الأخرى مع وجود فرق معنوي ($P = 0.863$). كما أظهرت الدراسة دلالة معنوية إحصائية مقاومة فطر المبيضات البيض لمضادات الفطريات فلوكونازول وإيتراكونازول وفلوكونازول مع قدرته على تكوين الغشاء الحيوي. سلطت الدراسة الحالية الضوء على معدل انتشار أعلى بكثير لمقاومة مضادات الفطريات بين المبيضة البيضاء وارتفاع معدل انتشار جين ERG11 في المبيضة البيضاء. وكذلك وجود علاقة قوية بين تكوين الأغشية الحيوية ووجود جين المضاد للعلاجات الفطرية. إن داء المبيضات هو أحد الالتهابات الفطرية الأكثر انتشاراً بين المرضى، كما أن عامل ضراوة الغشاء الحيوي (الببوفيلم) له دور مهم في زيادة القدرة المرضية للفطر.

الكلمات المفتاحية: حساسية للمضادات الحيوية، الغشاء الحيوي، المبيضات البيض، ERG1 ، الضراوة.